Key senators eye new, more ambitious legislation to lower insulin prices

WASHINGTON — Key Senate lawmakers have begun writing a bipartisan bill that would cap the prices patients pay for insulin — and target the strategies drugmakers use to set prices for the medicine, too.

The package, from Sens. Jeanne Shaheen (D-N.H.) and Sen. Susan Collins (R-Maine), would go beyond the $35-a-month cap lawmakers have been talking about for months, Shaheen suggested in a brief interview with STAT on Tuesday.

“We’re hopeful that we will have a bill that will address not just the cost cap… but the underlying cost,” she said.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In